Type 2 diabetes mellitus is a chronic hyperglycemic disorder caused by insulin resistance and progressive insulin secretory dysfunction. It accounts for the vast majority of diabetes cases globally.
Alnylam reported full-year 2025 profitability and $2.987 billion in global net product revenues, driven by U.S. approval and growth of AMVUTTRA. The company also outlined 2026 pipeline goals and additional HELIOS-B analyses for vutrisiran.
Two studies of older adults with type 2 diabetes linked diabetic retinal disease with higher dementia risk. DME and more severe diabetic retinopathy were associated with higher all-cause and vascular dementia risk, but not consistently with Alzheimer’s disease.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
A multicenter retrospective cohort study of 17 patients with type 2 diabetes and end-stage renal disease found injectable semaglutide was associated with descriptive changes in glycemic control and body weight. No cardiovascular deaths, nonfatal myocardial infarctions, or nonfatal strokes were observed during follow-up.
People with blood type B have a 28% higher risk of type 2 diabetes, while artificial sweetener consumption is linked to faster cognitive decline, particularly in younger adults and those with diabetes. The blood type finding comes from an umbrella review of 51 systematic reviews, while the sweetener study followed 12,772 Brazilian adults for eight years.
Oral semaglutide demonstrated significant improvements in multiple cardiometabolic risk factors in adults with type 2 diabetes at high cardiovascular risk. The SOUL trial analysis showed reductions in systolic blood pressure, cholesterol, triglycerides, HbA1c, and body weight compared to placebo. These benefits were observed as early as 13 weeks and contributed to a 14% reduction in major adverse cardiovascular events.
New research reveals how GLP-1 receptor agonists promote pancreatic health through gene expression changes and interact bidirectionally with gut microbiome, while real-world users report unexpected lifestyle changes alongside weight loss.
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
Zydus Lifesciences plans to launch Semaglutide injection in India after patent expiry and introduced ANYRA, India's first indigenous Aflibercept biosimilar. The USFDA cleared the company's Ahmedabad injectable facility with zero observations.
NATCO Pharma has licensed its semaglutide generic formulation to Eris Lifesciences for the Indian market, with a launch expected in March 2026 following CDSCO approval. The partnership targets type 2 diabetes management as the molecule loses patent exclusivity in India.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07599293 |
Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data |
ACTIVE_NOT_RECRUITING | |
| NCT07579702 |
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System |
NOT_YET_RECRUITING | NA |
| NCT07569744 |
Resveratrol for Endothelial Dysfunction and Metabolic Control in Type 2 Diabetes |
NOT_YET_RECRUITING | NA |
| NCT07560800 |
Effect of Beetroot Juice on Cardiovascular and Autonomic Responses to Exercise in Adults With Type 2 Diabetes |
NOT_YET_RECRUITING | NA |
| NCT07554469 |
An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score |
NOT_YET_RECRUITING | |
| NCT07541456 |
Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes |
COMPLETED | PHASE4 |
| NCT07538505 |
Testing a Diabetes Care Program in Rural and Low-Income Clinics |
NOT_YET_RECRUITING | NA |
| NCT07527650 |
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus |
NOT_YET_RECRUITING | PHASE2 |
| NCT07521475 |
Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes |
NOT_YET_RECRUITING | NA |
| NCT07492563 |
Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay |
NOT_YET_RECRUITING |
